Kevin Koch, Ph.D., President and Chief Executive Office
Portrait

Kevin Koch, Ph.D., has served as our President, Chief Executive Officer and a member of our board of directors since 2017 and has been in the life science industry for over 30 years with a focus on drug discovery, translational medicine and clinical development. Since 2016, he has also served as a Venture Partner with OrbiMed. Dr. Koch previously served as the Senior Vice President of Drug Discovery, Chemical and Molecular Therapeutics at Biogen where he managed global drug discovery and biomarker development. Dr. Koch was a co-founder of Array BioPharma, serving as President, Chief Scientific Officer and board member from the company’s inception in 1998 to 2013. While there, he built a fully integrated research and development team that oversaw the invention of over 20 clinical development candidates across multiple therapeutic areas, several of which are now marketed medicines. Prior to Array, Dr. Koch held senior positions at Amgen and Pfizer Central Research. Dr. Koch received a B.S. in Chemistry and Biochemistry from State University of New York, Stony Brook, and his Ph.D. in Synthetic Organic Chemistry from University of Rochester.

Alan Russell, Ph.D., Co-Founder and Chief Scientific Officer
Portrait

Alan Russell, Ph.D., serves as our Co-Founder, Chief Scientific Officer and a member of our board of directors. Previously, Dr. Russell served at GlaxoSmithKline as VP and Head of the Muscle Metabolism Discovery Performance Unit, leading a broad discovery and development effort focused on patients for whom muscle function is compromised. Prior to this, he worked at Cytokinetics Inc. and is the co-inventor of Tirasemtiv and Reldesemtiv, direct muscle sensitizers in clinical trials for Amyotrophic Lateral Sclerosis (ALS). Dr. Russell received a B.Pharm. in Pharmacy and Pharmacology and Ph.D. in Cell Biology and Gene Therapy from the University of Bath in the UK and Postdoctoral training at the Stanford University School of Medicine.

R. Michael Carruthers, Chief Financial Officer
Portrait

Michael Carruthers has served as our Chief Financial Officer since September 2020. Mr. Carruthers has over 20 years of experience serving as Chief Financial Officer for publicly-traded biopharmaceutical companies, with extensive experience across corporate finance and strategic planning including IPOs, secondary offerings and M&A transactions. Most recently, Mr. Carruthers consulted as Chief Financial Officer for several private and public companies. Previously, Mr. Carruthers served as Interim President of Nivalis Therapeutics, a publicly traded company acquired by Alpine Immune Sciences, in 2017 and Chief Financial Officer and Secretary from 2015 to 2017. From 1998 to 2015, he served as Chief Financial Officer for Array BioPharma Inc., a publicly traded company acquired by Pfizer Inc. Prior to this, he served as Chief Financial Officer of Sievers Instruments, Treasurer and Controller for the Waukesha division of Dover Corporation and Accountant with Coopers & Lybrand. Mr. Carruthers serves on the boards of Elevation Oncology (Nasdaq: ELEV) and OnKure, Inc., a privately-held biopharmaceutical company. Mr. Carruthers received a B.S. in accounting from the University of Colorado and a M.B.A. from the University of Chicago.

Behrad Derakhshan, Ph.D., Chief Business Officer
Portrait

Behrad Derakhshan, Ph.D. has served as Chief Business Officer since September 2020 and is responsible for our corporate strategy and business development. Dr. Derakhshan brings more than 10 years of experience in the rare/ultra-rare disease space. Most recently, Dr. Derakhshan served as Chief Business Officer at VectivBio, a clinical-stage biotechnology company focused on developing novel therapeutics across a variety of rare conditions where he was responsible for the company’s capital formation and business development strategy. Dr. Derakhshan previously served as the Head of Business Development at Therachon, a biotechnology company focused on the discovery and development of therapeutics for rare pediatric conditions until its acquisition by Pfizer Inc. in 2019. Prior to Therachon, he was a Director at Alexion Pharmaceuticals responsible for Business Development and Strategic Evaluation after initially leading the New Products Global Commercial Insights and Analytics team. Earlier in his career, Dr. Derakhshan worked in management consulting, first as a Senior Consultant at Easton Associates and then as an Associate Director at Navigant Consulting. During that time, he advised a number of global pharmaceutical and biotechnology companies across a range of strategic projects. Dr. Derakhshan conducted his postdoctoral training at the Yale School of Medicine and received his Ph.D. in Biochemistry from a joint program between Weill Cornell Medicine, New York and the University of Surrey, UK. He received a First-Class Honors BSc. with distinction in Biochemistry from the University of Surrey.

Joanne M. Donovan, M.D., Ph.D., Chief Medical Officer
Portrait

Joanne M. Donovan, M.D., Ph.D., has served as our Chief Medical Officer since 2021. Most recently, Dr. Donovan served as Chief Medical Officer and Senior Vice President, Clinical Development at Catabasis Pharmaceuticals. Since 1989, she has been a staff physician at the VA Boston Healthcare System, where she was formerly Chief of Gastroenterology. Dr. Donovan has held an appointment at Harvard Medical School since 1990, most recently as associate clinical professor of medicine. From 1998 to 2011, Dr. Donovan served in positions of increasing responsibility, ultimately as vice president of clinical development, at Genzyme, a biotechnology company, which she joined through its acquisition of GelTex Pharmaceuticals. Dr. Donovan holds a Ph.D. in medical engineering and medical physics from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and an S.B. from the Massachusetts Institute of Technology. She completed residency training in internal medicine and a fellowship in gastroenterology at the Brigham and Women's Hospital.

John Moore, General Counsel
Portrait

John Moore has served as our General Counsel since September 2020. He has many years of experience as General Counsel for small molecule biopharmaceutical companies working in a range of therapeutic areas. Mr. Moore was most recently General Counsel and Secretary at Peloton Therapeutics, where he led the legal aspects of the company’s initial public offering efforts and advised on its acquisition by Merck on the eve of its planned IPO. Prior to Peloton, Mr. Moore served for 15 years as General Counsel and Secretary at Array BioPharma, Inc. and for 5 years on the board of directors of Nivalis Therapeutics. Prior to Array, he was an attorney in private practice with Wilson Sonsini. Mr. Moore holds a B.S. in chemistry from the University of North Carolina, an M.S. in biochemistry from the University of Illinois and a J.D. from the University of North Carolina.

Abby Bronson, M.B.A., Vice President, Patient Advocacy and External Innovation
Portrait

Abby Bronson has served as our Vice President of Patient Advocacy and External Innovation since April 2020. Ms. Bronson recently served as the Senior Vice President of Research Strategy at Parent Project Muscular Dystrophy (PPMD) where she managed the research portfolio and developed novel trial strategies to accelerate the clinical trial process in Duchenne. Prior to PPMD, she was the Director of Operations at the Division of Clinical Innovation at NCATS, NIH. She has also had senior positions at MedImmune and Children’s National Medical Center. She holds an M.B.A. from the Wharton School of Business at the University of Pennsylvania and a B.A. from the University of Vermont.